Atorvastatin 20 Mg Oral Tablet

DRUG3 trials

Sponsors

First Affiliated Hospital Xi'an Jiaotong University, ANRS, Emerging Infectious Diseases, Taipei Medical University Shuang Ho Hospital

Conditions

Atherosclerotic Cardiovascular DiseaseAutosomal Dominant Polycystic Kidney DiseaseCOVID-19COVID-19 Drug TreatmentChronic Kidney DiseasesSevere Acute Respiratory Syndrome Coronavirus 2

Phase 2

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

CompletedNCT04466241

ANRS, Emerging Infectious DiseasesCOVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2

Start: 2020-11-27End: 2021-11-01Updated: 2024-12-27

Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

Enrolling by invitationNCT05870007

Taipei Medical University Shuang Ho HospitalAutosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases

Start: 2023-05-31End: 2026-12-31Target: 30Updated: 2023-05-23

Unknown Phase

How Atorvastatin Affects the Gut Flora and Metabolomics?

First Affiliated Hospital Xi'an Jiaotong UniversityAtherosclerotic Cardiovascular Disease

Start: 2017-11-13End: 2021-06-01Target: 30Updated: 2020-01-02

Related Papers

Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial.

2024-10-23

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial.

2021-12-2028 citations